Key result
Specific gene mutations link to athletic performance, with ACE I tied to ~88% greater endurance.
Why the study?
Molecular biology tools offer the potential for precision athlete management, including genetic profiling, biomarker monitoring, and pharmacogenomic individualization to transform talent identification, training periodization, and injury prevention.
Multi-layered genetic, pharmacogenomic, and immunological profiling can identify performance-associated variants and monitor training stress in elite athletes, though individual genetic variants have small effect sizes.
Answers are grounded in this paper and cite their sources.
Supports profiling to identify variants and monitor training stress in elites; extends associations but leaves open routine use given small effect sizes.
Background: The emergence of molecular biology tools in sport has ushered in an era of precision athlete management, in which genetic profiling, biomarker monitoring, and pharmacogenomic individualization promise to transform talent identification, training periodization, and injury prevention. Purpose: This applied review synthesizes findings from a multi-year national sports science research program (2006-2009) involving 127 elite athletes from Greco-Roman wrestling, canoe/kayak sprint, rowing, and weightlifting, and contextualizes them within the current state of sports genomics, pharmacogenomics, and exercise immunology. Methods: The program employed real-time polymerase chain reaction (qPCR) to genotype athletes for polymorphisms in ACE, AGT, ACTN3, AMPD1, MYH7, VDR, COL1A1, and CALCR genes. Pharmacogenetic profiles were constructed using DNA microchip technology targeting cytochrome P450 enzymes and glutathione S-transferases. Longitudinal immune monitoring included flow cytometric lymphocyte subset analysis, quantitative viral load assessment, and cytokine gene expression profiling. Results: Mutations in AGT, AGT2R1, ACTN3, and AMPD1 were significantly associated with physical performance phenotypes. Pharmacogenetic profiling revealed inter-individual variation in response to whey colostrum and branched-chain amino acid supplementation based on CYP and GST genotypes. Immune monitoring documented training-load-dependent viral reactivation, NK cell suppression, and CD4/CD8 ratio inversion during intensive training mesocycles. Mechano growth factor (MGF) was detected exclusively in working and mechanically damaged muscle tissue. Conclusions: The integration of genetic, immunological, pharmacogenomic, and biomarker data within a single national program demonstrates the feasibility and potential of precision sport science. While individual genetic variants explain only a small fraction of performance variance, multi-layered profiling approaches may enhance individualized training prescription and athlete health management.
No takes yet. Share an insight, caveat, or question.
Andreev et al. (2026) studied this question. Genetic profiling and pharmacogenomic individualization vs. Standard training protocols was evaluated on Association of genetic polymorphisms with athletic performance (OR 1.88, 95% CI 1.51-2.34). Mutations in AGT, ACTN3, and AMPD1 were associated with athletic performance phenotypes, with the ACE I allele linked to higher endurance performance.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: